Array BioPharma to Present ARRY-520 / KSP Inhibitor Data at 2010 ASH Annual Meeting
BOULDER, Colo.--(BUSINESS WIRE)--Nov 29, 2010 - Array BioPharma Inc. (NASDAQ: ARRY) today announced that it will present data from a Phase 1 trial of KSP inhibitor ARRY-520 in patients with relapsed/refractory multiple myeloma at the 2010 Annual Meeting of the American Society of Hematology (ASH) in Orlando, Florida on Saturday, December 4, 2010.
The abstract can be accessed through the ASH website, www.hematology.org/Meetings/Annual-Meeting. The abstract title is provided below, however, please note that according to ASH policy, all data is embargoed until the time of the beginning of the presentation. The poster will be available as a PDF after it is presented on Array's website at www.arraybiopharma.com.
|2010 Annual Meeting of the American Society of Hematology|
|A Phase 1/2 Trial of the
KSP Inhibitor ARRY-520 in Relapsed/Refractory Multiple Myeloma
|Saturday, December 4, 2010|
|5:30 – 7:30 p.m. E.T.|
|Orange County Convention Center, Hall A3/A4, Poster Board no.: I-939|
Array BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small-molecule drugs to treat patients afflicted with cancer and inflammatory diseases. Our proprietary drug development pipeline includes clinical candidates that are designed to regulate therapeutically important target proteins and are aimed at significant unmet medical needs. For more information on Array, please go to www.arraybiopharma.com.
Contact: Array BioPharma Inc.
Tricia Haugeto, 303-386-1193
Posted: November 2010